Crescent Biopharma (CBIO) EBT Margin (2013 - 2026)
Crescent Biopharma (CBIO) reported EBT Margin of 2240.9% for Q1 2026, up 87.33% on a QoQ basis from 17690.09% in Q2 2022.
Crescent Biopharma (CBIO) has 8 years of EBT Margin data on file, last reported at 2240.9% in Q1 2026.
- Quarterly EBT Margin changed N/A year-over-year to 2240.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15406.83% (changed N/A YoY) and the FY2025 annual result came in at 1401.16%, changed N/A from the prior year.
- EBT Margin advanced to 2240.9% in Q1 2026 per CBIO's latest filing, from 17690.09% in the prior quarter.
- Across five years, EBT Margin topped out at 2240.9% in Q1 2026 and bottomed at 17690.09% in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -2,240.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,240.90% |
| Jun 30, 2022 | -17,690.09% |
| Dec 31, 2021 | -98,847.07% |
| Sep 30, 2021 | -20,023.48% |
| Jun 30, 2021 | -10,140,324.65% |
| Mar 31, 2021 | -1,352.43% |
| Dec 31, 2020 | -9,551.50% |
| Sep 30, 2020 | -1,372.25% |
| Mar 31, 2020 | -85.14% |
| Sep 30, 2016 | -42,631.11% |
| Dec 31, 2015 | -25,123.75% |
| Sep 30, 2015 | -20,263.10% |
| Jun 30, 2015 | 51.95% |
| Jun 30, 2014 | 53.69% |
| Dec 31, 2013 | -4,995.73% |
| Sep 30, 2013 | -7,039.78% |
| Jun 30, 2013 | -6,349.75% |
| Mar 31, 2013 | 12.07% |